Childhood Cancer Research

Share

This year, more than 15,000 children under age 21 will be diagnosed with cancer.  And nearly 1/4 will not survive the disease.  Too many types of childhood cancer still have no known cure or treatment. 

We must ensure that researchers have the essential tools to fight childhood cancer and make sure children with cancer not only survive, but thrive. 

 

Over 14,000 U.S. children under age 20 will be diagnosed with cancer in 2016.

Take Action

Photo of children playing together

Tell Congress to Support Childhood Cancer and Pass the STAR Act

This lifesaving legislation will aid in the development of new treatments and improve the quality of life for kids not only while they receive cancer treatments, but throughout the rest of their lives.

Latest Updates

May 1, 2017

More than 200 childhood cancer advocates will be on Capitol Hill on May 2 to ask Congress to support initiatives that would increase research and improve treatment, leading to better outcomes for children with cancer.

April 3, 2017

ACS CAN applauds the introduction of the Research to Accelerate Cures and Equity (RACE) for Children Act (H.R. 1231/S. 456) – bipartisan legislation that would expand drug research for children with cancer, leading to better outcomes for pediatric patients.

February 3, 2017

The Childhood Cancer Survivorship, Treatment, Access and Research (STAR) Act (H.R. 820 and S. 292) introduced yesterday in Congress would help improve survivorship, treatment and access to care for childhood cancer patients and expand research into childhood cancers and care.

December 6, 2016

On December 6, the U.S. House of Representatives approved the bipartisan Childhood Cancer Survivorship, Treatment, Access and Research (STAR) Act, which advances pediatric cancer research and increases transparency and expertise for pediatric cancer research at the National Institutes of Health (NIH).

Childhood Cancer Research Resources

ACS CAN’s official endorsement of the RACE for Children Act, a bill that will encourage new research and development in childhood cancer.

This report examines the drug development landscape for childhood cancer, identifying scientific, logistical, economic and ethical challenges that are unique to pediatric cancer drug development.